8-K: 4D Molecular Therapeutics Announces Positive Interim Phase 2 Data for Wet AMD Treatment 4D-150

4D Molecular Therapeutics reported positive interim 24-week data from its Phase 2 PRISM trial for wet AMD treatment 4D-150, showing significant reductions in injection rates and improvements in visual acuity.

Summary

• 4D Molecular Therapeutics announced interim 24-week results from the Population Extension cohort of its Phase 2 PRISM trial for 4D-150, a treatment for wet age-related macular degeneration (wet AMD).
• The trial included 45 patients with varying disease activity, divided into two dose groups: 30 patients receiving the planned Phase 3 dose (3E10 vg/eye) and 15 patients receiving a lower dose (1E10 vg/eye).
• The planned Phase 3 dose group showed an 89% reduction in mean annualized injection rate, with 93% of patients receiving 0 or 1 injection and 77% being injection-free.
• The low dose group also showed a significant 91% reduction in mean annualized injection rate, with 100% receiving 0 or 1 injection and 60% being injection-free.
• Patients in the planned Phase 3 dose group experienced a +4.2 letter improvement in mean best corrected visual acuity (BCVA), with injection-free patients showing a +4.7 letter improvement.
• The planned Phase 3 dose group also demonstrated greater anatomic control with a -32 micron improvement in central subfield thickness (CST) for injection-free patients.
• Long-term follow-up data from the Phase 1 trial showed that patients treated with 3E10 vg/eye remained injection-free for approximately 2 to 2.5 years, with stable visual acuity and CST.
• 4D-150 has shown a favorable safety profile across all patients dosed to date (n=139) in both the PRISM and SPECTRA trials, with no significant inflammation or other serious adverse events.
• The company is working with regulatory agencies to finalize the Phase 3 trial design, expected to be announced in September 2024, with trial initiation anticipated in the first quarter of 2025.
• The company also expects to release 52-week landmark analysis for both its Dose Expansion and Population Extension cohorts in February 2025 and initial 24-week data from the SPECTRA trial for DME in the fourth quarter of 2024.

Sentiment

Score: 8

Explanation: The document presents very positive interim results for 4D-150, with strong efficacy and a favorable safety profile. The long-term follow-up data is also encouraging. The only minor negative is the mention of trace inflammation in a small number of patients. Overall, the sentiment is very positive.

Positives

• 4D-150 demonstrated a strong reduction in the need for anti-VEGF injections in wet AMD patients.
• The treatment showed a positive impact on visual acuity, with improvements observed in the planned Phase 3 dose group.
• The safety profile of 4D-150 was favorable, with no significant adverse events reported.
• Long-term data from the Phase 1 trial indicates sustained efficacy and safety.
• The planned Phase 3 dose showed a greater improvement in visual acuity compared to the low dose arm.
• The treatment showed a positive impact on retinal anatomy, with improvements observed in central subfield thickness (CST).

Negatives

• One patient in the low dose group experienced mild to moderate vitreous inflammation.
• Trace anterior chamber cells were noted in one patient in the low dose group.

Risks

• The company's future results are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated.
• The Phase 3 trial design is still being finalized with regulatory agencies.
• The success of the Phase 3 trial is not guaranteed.

Future Outlook

The company plans to announce the finalized Phase 3 clinical trial design in September 2024 and initiate the trial in the first quarter of 2025. They also expect to release additional data from ongoing trials in late 2024 and early 2025.

Industry Context

This announcement is significant in the context of the ongoing search for more effective and less frequent treatments for wet AMD, a leading cause of vision loss. The results suggest that 4D-150 could potentially reduce the treatment burden for patients, which is a major unmet need in the current treatment landscape.

Comparison to Industry Standards

• Current standard of care for wet AMD involves frequent anti-VEGF injections, typically every 4-8 weeks.
• The 89% reduction in mean annualized injection rate with 4D-150 is a significant improvement compared to the standard of care.
• Companies like Regeneron (Eylea) and Novartis (Lucentis, Beovu) are major players in the anti-VEGF market, and 4D-150's results suggest a potential competitive advantage.
• Other gene therapy companies like Adverum Biotechnologies are also developing treatments for wet AMD, but 4D-150's safety and efficacy data appear promising in comparison.
• The long-term follow-up data from the Phase 1 trial, showing sustained injection-free periods, is particularly noteworthy as it addresses a key limitation of current treatments.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical data.
• Patients with wet AMD may benefit from a more effective and less burdensome treatment option.
• The company's employees may be motivated by the positive results and progress of the clinical program.
• The company's suppliers and partners may see increased business opportunities.

Next Steps

• The company will finalize the Phase 3 clinical trial design with regulatory agencies.
• The Phase 3 clinical trial is expected to be initiated in the first quarter of 2025.
• The company will release 52-week landmark analysis for both its Dose Expansion and Population Extension cohorts in February 2025.
• The company will release initial 24-week landmark analysis from its SPECTRA trials Dose Confirmation cohort in the fourth quarter of 2024.

Key Dates

Keywords

4D-150, wet AMD, age-related macular degeneration, gene therapy, clinical trial, PRISM, anti-VEGF, visual acuity, injection rate, retina, ophthalmology